Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

706 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K. Alderuccio JP, et al. Among authors: farooq u. Blood Adv. 2021 Jul 27;5(14):2852-2862. doi: 10.1182/bloodadvances.2021004458. Blood Adv. 2021. PMID: 34283175 Free PMC article.
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Castellino A, Wang Y, Larson MC, Maurer MJ, Link BK, Farooq U, Feldman AL, Syrbu SI, Habermann TM, Paludo J, Inwards DJ, Witzig TE, Ansell SM, Allmer C, Slager SL, Cohen JB, Martin P, Cerhan JR, Nowakowski GS. Castellino A, et al. Among authors: farooq u. Blood Adv. 2022 Feb 22;6(4):1350-1360. doi: 10.1182/bloodadvances.2021005715. Blood Adv. 2022. PMID: 34662895 Free PMC article.
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Scordo M, et al. Among authors: farooq u. JAMA Oncol. 2021 Jul 1;7(7):993-1003. doi: 10.1001/jamaoncol.2021.1074. JAMA Oncol. 2021. PMID: 33956047 Free PMC article.
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Neelapu SS, et al. Among authors: farooq u. Blood Adv. 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848. Blood Adv. 2021. PMID: 34478487 Free PMC article.
Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Tun AM, et al. Among authors: farooq u. Transplant Cell Ther. 2022 Sep;28(9):610-617. doi: 10.1016/j.jtct.2022.06.015. Epub 2022 Jun 22. Transplant Cell Ther. 2022. PMID: 35752441 Free article.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Locke FL, et al. Among authors: farooq u. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. N Engl J Med. 2022. PMID: 34891224 Clinical Trial.
Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M. Fenske TS, et al. Among authors: farooq u. Br J Haematol. 2016 Jul;174(2):235-48. doi: 10.1111/bjh.14046. Epub 2016 Mar 15. Br J Haematol. 2016. PMID: 26989808 Free PMC article.
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Ahmed S, et al. Among authors: farooq u. Biol Blood Marrow Transplant. 2019 Sep;25(9):1859-1868. doi: 10.1016/j.bbmt.2019.05.025. Epub 2019 May 25. Biol Blood Marrow Transplant. 2019. PMID: 31132455 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36164119
706 results